Dose-dependent in vivo efficacy of TAK-676 was tested in multiple mouse syngeneic tumor models, including A20 (Fig. 4A) and CT26.WT (Fig. 4B) syngeneic tumor models. Here, DDX53 is linked to neoplasm.